Author

Xiao Zhu

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Beyond Pharmacokinetics: Gaps for Rational Use of Medicinal Cannabis

Standardized recording of product provenance in future clinical trials, through a structured reporting checklist, would help close the first gap, and confirmation of administered dose, such as biochemical verification of intake or electronic dose-monitoring devices, would help address the second.

Shuang Lu, Xin Liu, L. Truong et al. · Journal of clinical pharmaco... · 0 citations

Aug 2026

Model-informed dose optimization of etrasimod in ulcerative colitis across CYP2C9 genotypes and hepatic impairment.

In Chinese populations, hepatic impairment and CYP2C9 polymorphisms increased etrasimod exposure, with the greatest increase observed in CYP2C9 poor metabolizers with Child-Pugh C hepatic impairment (67% increase in AUCss).

Zi-Han Xu, Fangyi Qian, Yi-Ke Liu et al. · British Journal of Clinical... · 0 citations

Aug 2026

Adenosine 2A receptor drives microglial efferocytosis to accelerate white matter repair and functional recovery after stroke.

It is demonstrated that microglial adenosine 2A receptor (A2AR) is essential for spontaneous white matter regeneration after ischemic injury in mice and identified A2AR as a critical regulator of microglia-mediated white matter repair and a promising therapeutic target for enhancing regeneration after stroke.

Yanfang Deng, Qian He, Bolin Yao et al. · Science Signaling · 0 citations